Risk of a second breast cancer associated with hormone-receptor and HER2/neu status of the first breast cancer (Q33946233)

30 July 2017

title

Risk of a second breast cancer associated with hormone-receptor and HER2/neu status of the first breast cancer (English)

1 reference

30 July 2017

1 reference

5

Hoda Anton-Culver

0 references

author name string

Leona Bessonova

1

1 reference

30 July 2017

Thomas H Taylor

2

1 reference

30 July 2017

Rita S Mehta

3

1 reference

30 July 2017

Jason A Zell

4

1 reference

30 July 2017

publication date

7 January 2011

1 reference

Cancer Epidemiology, Biomarkers & Prevention

30 July 2017

published in

1 reference

30 July 2017

volume

20

1 reference

30 July 2017

issue

2

1 reference

30 July 2017

page(s)

389-396

1 reference

Diagnosis of second breast cancer events after initial diagnosis of early stage breast cancer

30 July 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4110060

American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4110060

Patterns and correlates of adjuvant radiotherapy receipt after lumpectomy and after mastectomy for breast cancer

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4110060

Neutrophil count in African Americans: lowering the target cutoff to initiate or resume chemotherapy?

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4110060

Second primary breast cancer occurrence according to hormone receptor status

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4110060

28 July 2018

Cancer statistics, 2009

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4110060

Adjuvant hormonal therapy use among insured, low-income women with breast cancer

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4110060

Prognostic impact of human epidermal growth factor-like receptor 2 and hormone receptor status in inflammatory breast cancer (IBC): analysis of 2,014 IBC patient cases from the California Cancer Registry

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4110060

Trastuzumab in inflammatory breast cancer

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4110060

American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004.

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4110060

Performance status score: do patients and their oncologists agree?

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4110060

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4110060

Toxicity and response criteria of the Eastern Cooperative Oncology Group

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4110060

A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4110060

Risk of second breast cancer according to estrogen receptor status and family history.

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4110060

Tumor marker phenotype concordance in second primary breast cancer, California, 1999-2004.

29 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4110060

Metronomic schedule of paclitaxel is effective in hormone receptor-positive and hormone receptor-negative breast cancer

29 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4110060

Dose-dense and/or metronomic schedules of specific chemotherapies consolidate the chemosensitivity of triple-negative breast cancer: a step toward reversing triple-negative paradox

29 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4110060

Malignancies following in situ cervical cancer in Hispanic Americans and non-Hispanic Whites

29 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4110060

A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer

29 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4110060

The California tumor registry: a state-of-the-art model for a regionalized, automated, population-based registry.

29 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4110060

Statistical methods in cancer research. Volume IV. Descriptive epidemiology

29 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4110060

Treatment of primary breast cancer with chemotherapy and tamoxifen

29 October 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/21217087

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Tamoxifen and contralateral breast cancer

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/21217087

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Adjuvant chemotherapy with and without tamoxifen in the treatment of primary breast cancer: 5-year results from the National Surgical Adjuvant Breast and Bowel Project Trial

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/21217087

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1158/1055-9965.EPI-10-1016

1 reference

30 July 2017

1 reference

30 July 2017

1 reference